4.7 Article

CD47-targeted immunotherapy unleashes antitumour immunity in Epstein-Barr virus-associated gastric cancer

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Multidisciplinary Sciences

The cGAS-STING pathway drives type I IFN immunopathology in COVID-19

Jeremy Di Domizio et al.

Summary: This study reveals the mechanism behind aberrant type I interferon responses in COVID-19 through the cGAS-STING pathway and demonstrates its importance in severe cases. By using animal and lung-on-chip models, the study provides insights into host-directed therapeutic strategies for COVID-19.

NATURE (2022)

Article Oncology

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy

Huanpeng Chen et al.

Summary: This study developed CAR-T cells that can secrete a CD47 blocker, enhancing the therapeutic efficacy of CAR-T cells in solid tumor therapy. The results showed that these CAR-T cells significantly reduced tumor burden, prolonged survival, and modulated the tumor microenvironment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Hematology

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Kristina Mueller et al.

Summary: This study suggests that combining CD47 blockade with Dara is a promising therapy for T-ALL, especially for relapsed/refractory disease harboring a dismal prognosis in patients.
Review Biochemistry & Molecular Biology

How the ends signal the end: Regulation by E3 ubiquitin ligases recognizing protein termini

Dawafuti Sherpa et al.

Summary: E3 ubiquitin ligases interact with protein termini to intricately control protein quality and cellular signaling.

MOLECULAR CELL (2022)

Article Cell Biology

DDX41 is required for cGAS-STING activation against DNA virus infection

Ravi Shankar Singh et al.

Summary: The DDX41 protein plays a crucial role in the activation of the cGAS-STING pathway, which is responsible for the production of type I interferon after DNA virus infection. DDX41 regulates cGAS and STING activation, and its mutant form, R525H, shows enhanced cGAS activity. The findings suggest that DDX41 functions by unwinding and annealing DNA to maintain the balance of dsDNA and ssDNA, thus regulating cGAS-STING activation.

CELL REPORTS (2022)

Article Medicine, Research & Experimental

Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma

Dongjiang Chen et al.

Summary: TTFields, a novel therapy for GBM and other solid tumors, disrupts mitotic spindle and induces inflammation to exert its anti-tumor effects. The study reveals that TTFields can activate DNA sensors and inflammasomes to produce immune response, leading to antitumor immunity and cure.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Article Medicine, Research & Experimental

SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling

Chuan Xu et al.

Summary: Signal regulatory protein gamma (SIRP gamma) determines the properties and immune evasiveness of cancer stem-like cells (CSLCs) in a small population of lung adenocarcinoma (LUAD) cancer cells. SIRP gamma activates the Hippo/YAP signaling pathway to release cytokines and stimulate CD47 expression in tumor cells, inhibiting their phagocytosis. Targeting SIRP gamma can inhibit CSLC phenotypes and promote tumor phagocytosis, making it an immune and CSLC-targeting strategy for lung cancer therapy.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Letter Biochemistry & Molecular Biology

ASTE1 frameshift mutation triggers the immune response in Epstein-Barr virus-associated gastric cancer

Binhao Huang et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

Article Immunology

Macrophages in tumor: An inflammatory perspective

Kuntal Kanti Goswami et al.

CLINICAL IMMUNOLOGY (2021)

Review Oncology

Targeting CD47 for cancer immunotherapy

Zhongxing Jiang et al.

Summary: Significant progress has been made in targeting CD47 for cancer immunotherapy in solid tumors and hematological malignancies, with a total of 46 clinical trials related to CD47 in the USA and 23 in China. Most of the trials are in early phases, and the new generation CD47 antibodies have shown promising results.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Article Oncology

Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers

Chunhong Hu et al.

Summary: Patients with MPLCs often present in non-smoking women younger than 60 years, with EGFR being the most frequently mutated gene. Shared putative driver genes between tumors indicate more aggressive tumors. MPLCs exhibit low TMB, low PD-L1 positivity, and a heterogeneous immune infiltration landscape.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Oncology

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer

Xu Cao et al.

Summary: The study found that blocking CD47 and using cabazitaxel can significantly promote the programmed cell removal of TNBC cells, inhibiting tumor development and metastasis, providing a promising new strategy for TNBC treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Review Immunology

The cGAS-STING pathway as a therapeutic target in inflammatory diseases

Alexiane Decout et al.

Summary: The cGAS-STING signaling pathway plays a crucial role in inflammation in infection, cellular stress, and tissue damage settings. It has the ability to sense and regulate cellular responses to DNA and has the potential to be targeted in the treatment of various inflammatory diseases.

NATURE REVIEWS IMMUNOLOGY (2021)

Article Biochemistry & Molecular Biology

Glutaminyl cyclase is an enzymatic modifier of the CD47-SIRPα axis and a target for cancer immunotherapy

Meike E. W. Logtenberg et al.

NATURE MEDICINE (2019)

Review Immunology

Macrophages as regulators of tumour immunity and immunotherapy

David G. DeNardo et al.

NATURE REVIEWS IMMUNOLOGY (2019)

Review Oncology

Outlooks on Epstein-Barr virus associated gastric cancer

Madiha Naseem et al.

CANCER TREATMENT REVIEWS (2018)

Review Oncology

Cancer immunotherapy targeting the CD47/SIRPα axis

Kipp Weiskopf

EUROPEAN JOURNAL OF CANCER (2017)

Article Multidisciplinary Sciences

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Robert T. Manguso et al.

NATURE (2017)

Review Oncology

Tumour-associated macrophages as treatment targets in oncology

Alberto Mantovani et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

Article Biochemistry & Molecular Biology

Mitochondrial aldehyde dehydrogenase 2 protects gastric mucosa cells against DNA damage caused by oxidative stress

Yantao Duan et al.

FREE RADICAL BIOLOGY AND MEDICINE (2016)

Article Medicine, Research & Experimental

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

Kipp Weiskopf et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

Review Immunology

Control of adaptive immunity by the innate immune system

Akiko Iwasaki et al.

NATURE IMMUNOLOGY (2015)

Article Biochemical Research Methods

Robust enumeration of cell subsets from tissue expression profiles

Aaron M. Newman et al.

NATURE METHODS (2015)

Review Immunology

The ins and outs of MHC class II-mediated antigen processing and presentation

Paul A. Roche et al.

NATURE REVIEWS IMMUNOLOGY (2015)

Article Multidisciplinary Sciences

Comprehensive molecular characterization of gastric adenocarcinoma

Adam J. Bass et al.

NATURE (2014)

Article Multidisciplinary Sciences

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

Badreddin Edris et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

Article Multidisciplinary Sciences

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

Stephen B. Willingham et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)